The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid
Abstract
Background— Allopurinol has been shown to improve endothelial function in chronic heart failure. This study aimed to establish its mechanism of action and to construct a dose–response curve for the effect of allopurinol. Methods and Results— Two randomized, placebo-controlled, double-blind, crossover studies were performed for 1 month on patients with New York Heart Association Class II–III chronic heart failure, comparing 300 mg allopurinol, 600 mg allopurinol, and placebo for the first study and 1000 mg probenecid versus placebo in the second study. Endothelial function was assessed by standard forearm venous occlusion plethysmography. Allopurinol 600 mg/d significantly increased forearm blood flow response to acetylcholine compared with both allopurinol 300 mg/d and placebo (% change in forearm blood flow [mean±SEM]: 240.31±38.19% versus 152.10±18.21% versus 73.96±10.29%, P <0.001). For similar levels of urate lowering, the uricosuric agent probenecid had no effect on endothelial function. Sodium nitroprusside response was unchanged by all treatments. Vitamin C and acetylcholine coinfusion data showed that 600 mg/d allopurinol completely abolished the oxidative stress that was sensitive to high-dose vitamin C. Conclusions— For the first time, we have shown that a steep dose–response relationship exists between allopurinol and its effect on endothelial function. We also showed that the mechanism of improvement in endothelial function with allopurinol lies in its ability to reduce vascular oxidative stress and not in urate reduction. The reduction in vascular oxidative stress was profound because high-dose allopurinol totally abolished the oxidative stress that was sensitive to the high-dose vitamin C that was used in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heitzer, T., Schlinzig, T., Krohn, K., Meinertz, T., & Münzel, T. (2001) · Circulation · doi:10.1161/hc4601.099485 · Cited by 1,961
The measurement of volume changes in human limbs
Whitney, R. J. (1953) · The Journal of Physiology · doi:10.1113/jphysiol.1953.sp004926 · Cited by 1,489
Taddei, S., Virdis, A., Ghiadoni, L., Magagna, A., & Salvetti, A. (1998) · Circulation · doi:10.1161/01.cir.97.22.2222 · Cited by 762
Anker, S. D., Doehner, W., Rauchhaus, M., Sharma, R., Francis, D., Knosalla, C., Davos, C. H., Cicoira, M., Shamim, W., Kemp, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000065637.10517.a0 · Cited by 593
Doehner, W., Schoene, N., Rauchhaus, M., Leyva-Leon, F., Pavitt, D. V., Reaveley, D. A., Schuler, G., Coats, A. J. S., Anker, S. D., & Hambrecht, R. (2002) · Circulation · doi:10.1161/01.cir.0000017502.58595.ed · Cited by 565
Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C., & Brunetti, P. (2000) · Hypertension · doi:10.1161/01.hyp.36.6.1072 · Cited by 558
Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure
Farquharson, C. A. J., Butler, R., Hill, A., Belch, J. J. F., & Struthers, A. D. (2002) · Circulation · doi:10.1161/01.cir.0000022140.61460.1d · Cited by 504
Self-citationAllopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension
Butler, R., Morris, A. D., Belch, J. J. F., Hill, A., & Struthers, A. D. (2000) · Hypertension · doi:10.1161/01.hyp.35.3.746 · Cited by 463
Self-citationAllopurinol Improves Myocardial Efficiency in Patients With Idiopathic Dilated Cardiomyopathy
Cappola, T. P., Kass, D. A., Nelson, G. S., Berger, R. D., Rosas, G. O., Kobeissi, Z. A., Marbán, E., & Hare, J. M. (2001) · Circulation · doi:10.1161/hc4501.098928 · Cited by 436
Regoli, F., & Winston, G. W. (1999) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8637 · Cited by 403
Cited by
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Feig, D. I., Soletsky, B., & Johnson, R. J. (2008) · JAMA · doi:10.1001/jama.300.8.924 · Cited by 914
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834
Reactive oxygen species in cardiovascular disease
Sugamura, K., & Keaney (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.004 · Cited by 769
Sugar, Uric Acid, and the Etiology of Diabetes and Obesity
Johnson, R. J., Nakagawa, T., Sanchez-Lozada, L. G., Shafiu, M., Sundaram, S., Le, M., Ishimoto, T., Sautin, Y. Y., & Lanaspa, M. A. (2013) · Diabetes · doi:10.2337/db12-1814 · Cited by 760
Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease
Choi, H. K., & Curhan, G. (2007) · Circulation · doi:10.1161/circulationaha.107.703389 · Cited by 666
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Yu, M.-A., Sánchez-Lozada, L. G., Johnson, R. J., & Kang, D.-H. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328337da1d · Cited by 626
Hypothesis: Could Excessive Fructose Intake and Uric Acid Cause Type 2 Diabetes?
Johnson, R. J., Perez-Pozo, S. E., Sautin, Y. Y., Manitius, J., Sanchez-Lozada, L. G., Feig, D. I., Shafiu, M., Segal, M., Glassock, R. J., Shimada, M., et al. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0033 · Cited by 505
Uric acid and cardiovascular disease
Ndrepepa, G. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.046 · Cited by 498
Endothelial Dysfunction, Arterial Stiffness, and Heart Failure
Marti, C. N., Gheorghiade, M., Kalogeropoulos, A. P., Georgiopoulou, V. V., Quyyumi, A. A., & Butler, J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.082 · Cited by 488
Serum uric acid and the risk of cardiovascular and renal disease
Borghi, C., Rosei, E. A., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J. T., Manolis, A. J., Perez-Ruiz, F., & Mancia, G. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000701 · Cited by 463
The role of uric acid in the pathogenesis of human cardiovascular disease
Kanbay, M., Segal, M., Afsar, B., Kang, D.-H., Rodriguez-Iturbe, B., & Johnson, R. J. (2013) · Heart · doi:10.1136/heartjnl-2012-302535 · Cited by 454
Uric acid in metabolic syndrome: From an innocent bystander to a central player
Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., Lanaspa, M. A., Nakagawa, T., & Johnson, R. J. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.11.026 · Cited by 419
Impact of Oxypurinol in Patients With Symptomatic Heart Failure
Hare, J. M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W. S., Mann, D. L., Liu, P., Givertz, M. M., & Schwarz, R. P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.068 · Cited by 392
Thomas, S. R., Witting, P. K., & Drummond, G. R. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2027 · Cited by 383
“Several studies indicate that pharmacologic inhibition of xanthine oxidase partially improves endothelial function in patients with type-2 diabetes (62), CAD (29, 71, 171, 293), and chronic heart failure (143).”
Anti-inflammatory therapies for atherosclerosis
Bäck, M., & Hansson, G. K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.5 · Cited by 378
Uric acid and cardiovascular disease: A clinical review
Saito, Y., Tanaka, A., Node, K., & Kobayashi, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.12.013 · Cited by 374
New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity
Furuhashi, M. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00378.2020 · Cited by 361
Noman, A., Ang, D. S., Ogston, S., Lang, C. C., & Struthers, A. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60391-1 · Cited by 348
Self-citationUric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective
Yu, W., & Cheng, J.-D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.582680 · Cited by 344
Uric Acid Reduction Rectifies Prehypertension in Obese Adolescents
Soletsky, B., & Feig, D. I. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.196980 · Cited by 334
Established and Emerging Roles of Biomarkers in Heart Failure
Ibrahim, N. E., & Januzzi, J. L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312706 · Cited by 306
Goicoechea, M., Garcia de Vinuesa, S., Verdalles, U., Verde, E., Macias, N., Santos, A., Pérez de Jose, A., Cedeño, S., Linares, T., & Luño, J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.016 · Cited by 302
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview
Chen, C., Lü, J.-M., & Yao, Q. (2016) · Medical Science Monitor · doi:10.12659/msm.899852 · Cited by 302
Givertz, M. M., Anstrom, K. J., Redfield, M. M., Deswal, A., Haddad, H., Butler, J., Tang, W. H. W., Dunlap, M. E., LeWinter, M. M., Mann, D. L., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.014536 · Cited by 296
Protective Role for Antioxidants in Acute Kidney Disease
Dennis, J., & Witting, P. (2017) · Nutrients · doi:10.3390/nu9070718 · Cited by 291
Soltani, Z., Rasheed, K., Kapusta, D. R., & Reisin, E. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0344-5 · Cited by 272
Oxidative stress and the role of redox signalling in chronic kidney disease
Kishi, S., Nagasu, H., Kidokoro, K., & Kashihara, N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00775-0 · Cited by 267
Inactivation of Nitric Oxide by Uric Acid
Gersch, C., Palii, S. P., Kim, K. M., Angerhofer, A., Johnson, R. J., & Henderson, G. N. (2008) · Nucleosides, Nucleotides and Nucleic Acids · doi:10.1080/15257770802257952 · Cited by 253
Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis
Agarwal, V., Hans, N., & Messerli, F. H. (2013) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00701.x · Cited by 173
Higgins, P., Dawson, J., Lees, K. R., McArthur, K., Quinn, T. J., & Walters, M. R. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00277.x · Cited by 164
“The effect of variable dose (100 mg/300 mg once daily) [16] and (300 mg once daily/300 mg twice daily) [27] was also studied.”
InfluentialAllopurinol and Cardiovascular Outcomes in Adults With Hypertension
MacIsaac, R. L., Salatzki, J., Higgins, P., Walters, M. R., Padmanabhan, S., Dominiczak, A. F., Touyz, R. M., & Dawson, J. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06344 · Cited by 124
Packer, M. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.08.015 · Cited by 95
Xanthine Oxidase Inhibitors in Heart Failure: Where Do We Go From Here?
Tamariz, L., & Hare, J. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016379 · Cited by 39
Shirakura, T., Nomura, J., Matsui, C., Kobayashi, T., Tamura, M., & Masuzaki, H. (2016) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-016-1239-1 · Cited by 36
Metadata
- Authors
- George, J., Carr, E., Davies, J., Belch, J. J. F., & Struthers, A.
- Venue
- Circulation
- Published
- 2006-12-05
- Volume
- 114
- Issue
- 23
- Pages
- 2508-2516
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2147978034
- Cited by
- 569
- References
- 36
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.